Exo-Fect™ Exosome Transfection Kit

Turn your exosomes into delivery vehicles with Exo-Fect—enables insertion of RNAs, DNAs (including plasmids), and small molecules into isolated exosomes.
  • Easy-to-use with a fast and straightforward loading protocol
  • Introduces a wide range of biomolecules directly into isolated exosomes:
    • RNAs, including siRNAs, miRNAs, and mRNAs
    • DNAs, including plasmids
    • Metabolites and other small molecules

Products

Catalog Number Description Size Price Quantity Add to Cart
EXFT10A-1 Exo-Fect Exosome Transfection Kit 10 Reactions $233
- +
EXFT20A-1 Exo-Fect Exosome Transfection Kit 20 Reactions $421
- +

Overview

Overview

Putting exosomes to work: Load your cargo directly into isolated exosomes With Exo-Fect, you can turn isolated exosomes into cargo delivery vehicles that introduce RNAs, DNAs (including plasmids), and even small molecules into recipient cells. Simply combine isolated exosomes with Exo-Fect and your desired cargo, and in less than an hour your loaded exosomes will be ready to add to recipient cells. Exo-Fect turns your exosomes into cargo delivery vehicles
  • Easy-to-use with a fast and straightforward loading protocol
  • Introduces a wide range of biomolecules directly into isolated exosomes:
    • RNAs, including siRNAs, miRNAs, and mRNAs
    • DNAs, including plasmids
    • Metabolites and other small molecules
  • Enables non-viral transduction and stable cell line creation
  • Provides an alternative gene delivery method for hard-to-transfect cells
All Exo-Fect Kits come with a Texas Red-labeled positive control, non-targeting siRNA to confirm exosome transfections. Pair with our EV-Entry Reagent and maximize cargo uptake by recipient cells.

How It Works

How It Works

Quickly and easily load cargo into isolated exosomes

Simply combine the isolated exosomes with Exo-Fect Reagent and cargo, perform two incubations for a total of 40 minutes, and then pellet your exosomes. The Kit comes with all of the reagents you need to load cargo into exosomes and concentrate them for delivery to target cells. The protocol takes less than an hour and is highly efficient at loading cargo into exosomes for transport and delivery.

Exo-Fect is also compatible with the EV-Entry Reagent, which maximizes cargo uptake by recipient cells.

Supporting Data

Supporting Data

See how Exo-Fect can be used to create cargo-delivering exosomes

Exo-Fect efficiently loads small RNAs into exosomes for delivery to recipient cells
 
Exo-Fect efficiently loads siRNA into exosomes.

Figure 1. Exo-Fect efficiently loads siRNA into exosomes. Fluorescence imaging shows exosomes that were loaded with either a Texas Red end-labeled siRNA (left panels), or unlabeled siRNA (right panels) using Exo-Fect, and then immobilized onto Exo-Flow™ CD63 magnetic beads.

Exo-Fect transfected exosomes deliver siRNA cargo to recipient cells

Figure 2. Exo-Fect transfected exosomes deliver siRNA cargo to recipient cells. The siRNA-loaded exosomes from Figure 1 were eluted from the Exo-Flow CD63 magnetic beads and then added to HEK293 cells. Fluorescence of the recipient cells indicates that the Texas Red-labeled siRNA cargo was successfully delivered.

Exo-Fect efficiently loads mRNAs and DNA plasmids into exosomes for delivery to recipient cells
 Exo-Fect loaded exosomes deliver mRNA and plasmid DNA into recipient cells

Figure 3. Exo-Fect loaded exosomes deliver mRNA and plasmid DNA into recipient cells. ExoFect Kits also work with larger nucleic acids, like mRNAs and plasmids. (Left panels) We used Exo-Fect to transfect 1 µg of an mRNA encoding RFP into exosomes. These exosomes were then added to HEK293 cells and imaged for RFP protein production after 24 hours. (Right panels) We used Exo-Fect to transfect 5 µg of plasmid DNA encoding a GFP gene into exosomes, and then added the plasmid-loaded exosomes to HEK293 cells. The cells were imaged for GFP protein presence after 48 hours. The appearance of RFP signal (mRNA cargo) and GFP signal (plasmid cargo) in recipient cells indicates successful cargo delivery.

Exo-Fect efficiently loads small molecules into exosomes for delivery to recipient cellsExo-Fect transfects the small molecule cumate into exosomesExo-Fect transfects the small molecule cumate into exosomes

Figure 4. Exo-Fect can even be used to transfect small molecules into exosomes. We loaded cumate into exosomes using Exo-Fect, and then added loaded exosomes to cells containing a cumate-inducible GFP reporter construct. Only cumate-containing exosomes were able to induce GFP expression in recipient cells, indicating successful delivery of cumate.

Resources

Citations

  • Lang, HL, et al. (2023) Small extracellular vesicles secreted by induced pluripotent stem cell-derived mesenchymal stem cells improve postoperative cognitive dysfunction in mice with diabetes. Neural regeneration research. 1970 Jan 1; 18(3):609-617. PM ID: 36018185
  • Nordmeier, S, Hsiung, F & Portnoy, V. (2022) Extracellular Vesicles (EVs). RNA Nanotechnology and Therapeutics. 1970 Jan 1;:377-382. Link: RNA Nanotechnology and Therapeutics
  • Wang, C, et al. (2022) Nicotine exacerbates endothelial dysfunction and drives atherosclerosis via extracellular vesicle-miRNA. Cardiovascular research. 1970 Jan 1;. PM ID: 36006370
  • Sheng, C, et al. (2022) Exosomes derived from human adipose-derived stem cells ameliorate osteoporosis through miR-335-3p/Aplnr axis. Nano Research. 1970 Jan 1;. Link: Nano Research
  • Cao, H, et al. (2022) Extracellular Vesicles-Encapsulated miR-153-3p Potentiate the Survival and Invasion of Lung Adenocarcinoma. Molecules and cells. 1970 Jan 1; 45(6):376-387. PM ID: 35611687
  • Esteves, M, et al. (2022) MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson’s disease. Molecular therapy : the journal of the American Society of Gene Therapy. 1970 Jan 1;. PM ID: 35689381
  • Gong, C, et al. (2022) HMSCs exosome-derived miR-199a-5p attenuates sulfur mustard-associated oxidative stress via the CAV1/NRF2 signaling pathway. Research Square. 1970 Jan 1;. Link: Research Square
  • Jayasinghe, M, et al. (2022) Surface-engineered extracellular vesicles for targeted delivery of therapeutic RNAs and peptides for cancer therapy. Theranostics. 1970 Jan 1; 12(7):3288-3315. Link: Theranostics
  • Kang, JY, et al. (2021) Co-delivery of curcumin and miRNA-144-3p using heart-targeted extracellular vesicles enhances the therapeutic efficacy for myocardial infarction. Journal of controlled release : official journal of the Controlled Release Society. 1970 Jan 1; 331:62-73. PM ID: 33460670
  • Xu, M, et al. (2021) Hydrogen Peroxide-Induced Senescence Reduces the Wound Healing-Promoting Effects of Mesenchymal Stem Cell-Derived Exosomes Partially via miR-146a. Aging and disease. 1970 Jan 1; 12(1):102. Link: Aging and disease
  • Pei, X, et al. (2021) Targeted exosomes for co-delivery of siFGL1 and siTGF-β1 trigger combined cancer immunotherapy by remodeling immunosuppressive tumor microenvironment. Chemical Engineering Journal. 1970 Jan 1; 421:129774. Link: Chemical Engineering Journal
  • Tai Tay, DJ, et al. (2021) Targeting RNA Editing of Antizyme Inhibitor 1: a Potential Oligonucleotide-Based Antisense Therapy for Cancer. Molecular therapy : the journal of the American Society of Gene Therapy. 1970 Jan 1;. PM ID: 33974998
  • Wu, D, et al. (2021) TGF-β1-mediated exosomal lnc-MMP2-2 increases blood-brain barrier permeability via the miRNA-1207-5p/EPB41L5 axis to promote non-small cell lung cancer brain metastasis. Cell death & disease. 1970 Jan 1; 12(8):721. PM ID: 34285192
  • Xun, J, et al. (2021) Serum exosomes from young rats improve the reduced osteogenic differentiation of BMSCs in aged rats with osteoporosis after fatigue loading in vivo. Stem cell research & therapy. 1970 Jan 1; 12(1):424. PM ID: 34315544
  • McAndrews, KM, et al. (2021) Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic KrasG12D in pancreatic cancer. Life science alliance. 1970 Jan 1; 4(9). PM ID: 34282051
  • Gunassekaran, GR, et al. (2021) M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 1970 Jan 1; 278:121137. PM ID: 34560422
  • Yee Mon, KJ, et al. (2021) MicroRNA-29 specifies age-related differences in the CD8+ T cell immune response. Cell reports. 1970 Jan 1; 37(6):109969. PM ID: 34758312
  • Qian, B, et al. (2021) M1 macrophage-derived exosomes impair beta cell insulin secretion via miR-212-5p by targeting SIRT2 and inhibiting Akt/GSK-3β/β-catenin pathway in mice. Diabetologia. 1970 Jan 1;. PM ID: 34117507
  • Bedoya, N. (2020) Impact of Bovine Milk Extracellular Vesicles and Their MicroRNA Cargoes on the Cardiovascular System. Thesis. 1970 Jan 1;. Link: Thesis
  • Sun, P, et al. (2020) Circulating Exosomes Control CD4+ T Cell Immunometabolic Functions via the Transfer of miR-142 as a Novel Mediator in Myocarditis. Mol. Ther.. 1970 Jan 1;. PM ID: 32882180

Products

Catalog Number Description Size Price Quantity Add to Cart
EXFT10A-1 Exo-Fect Exosome Transfection Kit 10 Reactions $233
- +
EXFT20A-1 Exo-Fect Exosome Transfection Kit 20 Reactions $421
- +

Overview

Overview

Putting exosomes to work: Load your cargo directly into isolated exosomes With Exo-Fect, you can turn isolated exosomes into cargo delivery vehicles that introduce RNAs, DNAs (including plasmids), and even small molecules into recipient cells. Simply combine isolated exosomes with Exo-Fect and your desired cargo, and in less than an hour your loaded exosomes will be ready to add to recipient cells. Exo-Fect turns your exosomes into cargo delivery vehicles
  • Easy-to-use with a fast and straightforward loading protocol
  • Introduces a wide range of biomolecules directly into isolated exosomes:
    • RNAs, including siRNAs, miRNAs, and mRNAs
    • DNAs, including plasmids
    • Metabolites and other small molecules
  • Enables non-viral transduction and stable cell line creation
  • Provides an alternative gene delivery method for hard-to-transfect cells
All Exo-Fect Kits come with a Texas Red-labeled positive control, non-targeting siRNA to confirm exosome transfections. Pair with our EV-Entry Reagent and maximize cargo uptake by recipient cells.

How It Works

How It Works

Quickly and easily load cargo into isolated exosomes

Simply combine the isolated exosomes with Exo-Fect Reagent and cargo, perform two incubations for a total of 40 minutes, and then pellet your exosomes. The Kit comes with all of the reagents you need to load cargo into exosomes and concentrate them for delivery to target cells. The protocol takes less than an hour and is highly efficient at loading cargo into exosomes for transport and delivery.

Exo-Fect is also compatible with the EV-Entry Reagent, which maximizes cargo uptake by recipient cells.

Supporting Data

Supporting Data

See how Exo-Fect can be used to create cargo-delivering exosomes

Exo-Fect efficiently loads small RNAs into exosomes for delivery to recipient cells
 
Exo-Fect efficiently loads siRNA into exosomes.

Figure 1. Exo-Fect efficiently loads siRNA into exosomes. Fluorescence imaging shows exosomes that were loaded with either a Texas Red end-labeled siRNA (left panels), or unlabeled siRNA (right panels) using Exo-Fect, and then immobilized onto Exo-Flow™ CD63 magnetic beads.

Exo-Fect transfected exosomes deliver siRNA cargo to recipient cells

Figure 2. Exo-Fect transfected exosomes deliver siRNA cargo to recipient cells. The siRNA-loaded exosomes from Figure 1 were eluted from the Exo-Flow CD63 magnetic beads and then added to HEK293 cells. Fluorescence of the recipient cells indicates that the Texas Red-labeled siRNA cargo was successfully delivered.

Exo-Fect efficiently loads mRNAs and DNA plasmids into exosomes for delivery to recipient cells
 Exo-Fect loaded exosomes deliver mRNA and plasmid DNA into recipient cells

Figure 3. Exo-Fect loaded exosomes deliver mRNA and plasmid DNA into recipient cells. ExoFect Kits also work with larger nucleic acids, like mRNAs and plasmids. (Left panels) We used Exo-Fect to transfect 1 µg of an mRNA encoding RFP into exosomes. These exosomes were then added to HEK293 cells and imaged for RFP protein production after 24 hours. (Right panels) We used Exo-Fect to transfect 5 µg of plasmid DNA encoding a GFP gene into exosomes, and then added the plasmid-loaded exosomes to HEK293 cells. The cells were imaged for GFP protein presence after 48 hours. The appearance of RFP signal (mRNA cargo) and GFP signal (plasmid cargo) in recipient cells indicates successful cargo delivery.

Exo-Fect efficiently loads small molecules into exosomes for delivery to recipient cellsExo-Fect transfects the small molecule cumate into exosomesExo-Fect transfects the small molecule cumate into exosomes

Figure 4. Exo-Fect can even be used to transfect small molecules into exosomes. We loaded cumate into exosomes using Exo-Fect, and then added loaded exosomes to cells containing a cumate-inducible GFP reporter construct. Only cumate-containing exosomes were able to induce GFP expression in recipient cells, indicating successful delivery of cumate.

Citations

  • Lang, HL, et al. (2023) Small extracellular vesicles secreted by induced pluripotent stem cell-derived mesenchymal stem cells improve postoperative cognitive dysfunction in mice with diabetes. Neural regeneration research. 1970 Jan 1; 18(3):609-617. PM ID: 36018185
  • Nordmeier, S, Hsiung, F & Portnoy, V. (2022) Extracellular Vesicles (EVs). RNA Nanotechnology and Therapeutics. 1970 Jan 1;:377-382. Link: RNA Nanotechnology and Therapeutics
  • Wang, C, et al. (2022) Nicotine exacerbates endothelial dysfunction and drives atherosclerosis via extracellular vesicle-miRNA. Cardiovascular research. 1970 Jan 1;. PM ID: 36006370
  • Sheng, C, et al. (2022) Exosomes derived from human adipose-derived stem cells ameliorate osteoporosis through miR-335-3p/Aplnr axis. Nano Research. 1970 Jan 1;. Link: Nano Research
  • Cao, H, et al. (2022) Extracellular Vesicles-Encapsulated miR-153-3p Potentiate the Survival and Invasion of Lung Adenocarcinoma. Molecules and cells. 1970 Jan 1; 45(6):376-387. PM ID: 35611687
  • Esteves, M, et al. (2022) MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson’s disease. Molecular therapy : the journal of the American Society of Gene Therapy. 1970 Jan 1;. PM ID: 35689381
  • Gong, C, et al. (2022) HMSCs exosome-derived miR-199a-5p attenuates sulfur mustard-associated oxidative stress via the CAV1/NRF2 signaling pathway. Research Square. 1970 Jan 1;. Link: Research Square
  • Jayasinghe, M, et al. (2022) Surface-engineered extracellular vesicles for targeted delivery of therapeutic RNAs and peptides for cancer therapy. Theranostics. 1970 Jan 1; 12(7):3288-3315. Link: Theranostics
  • Kang, JY, et al. (2021) Co-delivery of curcumin and miRNA-144-3p using heart-targeted extracellular vesicles enhances the therapeutic efficacy for myocardial infarction. Journal of controlled release : official journal of the Controlled Release Society. 1970 Jan 1; 331:62-73. PM ID: 33460670
  • Xu, M, et al. (2021) Hydrogen Peroxide-Induced Senescence Reduces the Wound Healing-Promoting Effects of Mesenchymal Stem Cell-Derived Exosomes Partially via miR-146a. Aging and disease. 1970 Jan 1; 12(1):102. Link: Aging and disease
  • Pei, X, et al. (2021) Targeted exosomes for co-delivery of siFGL1 and siTGF-β1 trigger combined cancer immunotherapy by remodeling immunosuppressive tumor microenvironment. Chemical Engineering Journal. 1970 Jan 1; 421:129774. Link: Chemical Engineering Journal
  • Tai Tay, DJ, et al. (2021) Targeting RNA Editing of Antizyme Inhibitor 1: a Potential Oligonucleotide-Based Antisense Therapy for Cancer. Molecular therapy : the journal of the American Society of Gene Therapy. 1970 Jan 1;. PM ID: 33974998
  • Wu, D, et al. (2021) TGF-β1-mediated exosomal lnc-MMP2-2 increases blood-brain barrier permeability via the miRNA-1207-5p/EPB41L5 axis to promote non-small cell lung cancer brain metastasis. Cell death & disease. 1970 Jan 1; 12(8):721. PM ID: 34285192
  • Xun, J, et al. (2021) Serum exosomes from young rats improve the reduced osteogenic differentiation of BMSCs in aged rats with osteoporosis after fatigue loading in vivo. Stem cell research & therapy. 1970 Jan 1; 12(1):424. PM ID: 34315544
  • McAndrews, KM, et al. (2021) Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic KrasG12D in pancreatic cancer. Life science alliance. 1970 Jan 1; 4(9). PM ID: 34282051
  • Gunassekaran, GR, et al. (2021) M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 1970 Jan 1; 278:121137. PM ID: 34560422
  • Yee Mon, KJ, et al. (2021) MicroRNA-29 specifies age-related differences in the CD8+ T cell immune response. Cell reports. 1970 Jan 1; 37(6):109969. PM ID: 34758312
  • Qian, B, et al. (2021) M1 macrophage-derived exosomes impair beta cell insulin secretion via miR-212-5p by targeting SIRT2 and inhibiting Akt/GSK-3β/β-catenin pathway in mice. Diabetologia. 1970 Jan 1;. PM ID: 34117507
  • Bedoya, N. (2020) Impact of Bovine Milk Extracellular Vesicles and Their MicroRNA Cargoes on the Cardiovascular System. Thesis. 1970 Jan 1;. Link: Thesis
  • Sun, P, et al. (2020) Circulating Exosomes Control CD4+ T Cell Immunometabolic Functions via the Transfer of miR-142 as a Novel Mediator in Myocarditis. Mol. Ther.. 1970 Jan 1;. PM ID: 32882180